{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:35:53Z","timestamp":1780590953575,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"funds for speaking at symposia organized on behalf of Pfizer, Novartis, Merck, Angelini, Thermofischer, Biomerieux, Basilea, Correvio, Zambon, Hikma and Astellas."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mid Regional pro-ADM (MR-proADM) is a promising novel biomarker in the evaluation of deteriorating patients and an emergent prognosis factor in patients with sepsis, septic shock and organ failure. It can be induced by bacteria, fungi or viruses. We hypothesized that the assessment of MR-proADM, with or without other inflammatory cytokines, as part of a clinical assessment of COVID-19 patients at hospital admission, may assist in identifying those likely to develop severe disease. A pragmatic retrospective analysis was performed on a complete data set from 111 patients admitted to Udine University Hospital, in northern Italy, from 25th March to 15th May 2020, affected by SARS-CoV-2 pneumonia. Clinical scoring systems (SOFA score, WHO disease severity class, SIMEU clinical phenotype), cytokines (IL-6, IL-1b, IL-8, TNF-\u03b1), and MR-proADM were measured. Demographic, clinical and outcome data were collected for analysis. At multivariate analysis, high MR-proADM levels were significantly associated with negative outcome (death or orotracheal intubation, IOT), with an odds ratio of 4.284 [1.893\u201311.413], together with increased neutrophil count (OR\u2009=\u20091.029 [1.011\u20131.049]) and WHO disease severity class (OR\u2009=\u20097.632 [5.871\u201319.496]). AUROC analysis showed a good discriminative performance of MR-proADM (AUROC: 0.849 [95% Cl 0.771\u20130.730]; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The optimal value of MR-proADM to discriminate combined event of death or IOT is 0.895\u00a0nmol\/l, with a sensitivity of 0.857 [95% Cl 0.728\u20130.987] and a specificity of 0.687 [95% Cl 0.587\u20130.787]. This study shows an association between MR-proADM levels and the severity of COVID-19. The assessment of MR-proADM combined with clinical scoring systems could be of great value in triaging, evaluating possible escalation of therapies, and admission avoidance or inclusion into trials. Larger prospective and controlled studies are needed to confirm these findings.<\/jats:p>","DOI":"10.1038\/s41598-021-84478-1","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T11:03:59Z","timestamp":1614855839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["MR-proADM as prognostic factor of outcome in COVID-19 patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Emanuela","family":"Sozio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D\u2019Aurizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ripoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pagotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Giacinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gerussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Visentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"De Stefanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kordo","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"84478_CR1","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jama.2020.5394","volume":"323","author":"G Grasselli","year":"2020","unstructured":"Grasselli, G. et al. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323, 1574\u20131581 (2020).","journal-title":"JAMA"},{"key":"84478_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nri2171","volume":"7","author":"JS Pober","year":"2007","unstructured":"Pober, J. S. & Sessa, W. C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 7, 803\u2013815 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"84478_CR3","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.3389\/fimmu.2020.02014","volume":"11","author":"S Meini","year":"2020","unstructured":"Meini, S. et al. Understanding the pathophysiology of COVID-19: could the contact system be the key?. Front. Immunol. 11, 2014. https:\/\/doi.org\/10.3389\/fimmu.2020.02014 (2020).","journal-title":"Front. Immunol."},{"key":"84478_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","volume":"180","author":"P Sinha","year":"2020","unstructured":"Sinha, P., Matthay, M. A. & Calfee, C. S. Is a \u201cCytokine Storm\u201d relevant to COVID-19?. JAMA Intern Med. 180, 1152\u20131154 (2020).","journal-title":"JAMA Intern Med."},{"key":"84478_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17052","author":"M Kox","year":"2020","unstructured":"Kox, M., Waalders, N. J. B., Kooistra, E. J., Gerretsen, J. & Pickkers, P. Cytokine levels in critically Ill patients with COVID-19 and other conditions. JAMA https:\/\/doi.org\/10.1001\/jama.2020.17052 (2020).","journal-title":"JAMA"},{"key":"84478_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"84478_CR7","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Invest."},{"key":"84478_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","volume":"20","author":"LA Teuwen","year":"2020","unstructured":"Teuwen, L. A., Geldhof, V., Pasut, A. & Carmeliet, P. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 20, 389\u2013391 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"84478_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13054-019-2329-5","volume":"23","author":"K Saeed","year":"2019","unstructured":"Saeed, K. et al. The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study. Crit. Care 23, 40. https:\/\/doi.org\/10.1186\/s13054-019-2329-5 (2019).","journal-title":"Crit. Care"},{"key":"84478_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13054-018-2001-5","volume":"22","author":"G Elke","year":"2018","unstructured":"Elke, G. et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis\u2014a secondary analysis of a large randomised controlled trial. Crit. Care 22, 79. https:\/\/doi.org\/10.1186\/s13054-018-2001-5 (2018).","journal-title":"Crit. Care"},{"key":"84478_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s13054-020-03151-7","volume":"24","author":"DC Wilson","year":"2020","unstructured":"Wilson, D. C. et al. Adrenomedullin in COVID-19 induced endotheliitis. Crit. Care 24, 411. https:\/\/doi.org\/10.1186\/s13054-020-03151-7 (2020).","journal-title":"Crit. Care"},{"key":"84478_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13054-020-03246-1","volume":"24","author":"J Hupf","year":"2020","unstructured":"Hupf, J. et al. RNA-expression of adrenomedullin is increased in patients with severe COVID-19. Crit. Care 24, 527. https:\/\/doi.org\/10.1186\/s13054-020-03246-1 (2020).","journal-title":"Crit. Care"},{"key":"84478_CR13","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-56715\/v1","author":"G Montrucchio","year":"2020","unstructured":"Montrucchio, G. et al. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: an observational prospective study. Crit. Care Emerg. Med. https:\/\/doi.org\/10.21203\/rs.3.rs-56715\/v1 (2020).","journal-title":"Crit. Care Emerg. Med."},{"key":"84478_CR14","unstructured":"World Health Organization. Clinical management of COVID-19\u2014interim guidance. https:\/\/www.who.int\/publications\/i\/item\/clinical-management-of-covid-19"},{"key":"84478_CR15","unstructured":"https:\/\/www.simeu.it\/w\/articoli\/leggiArticolo\/3964\/leggi"},{"key":"84478_CR16","unstructured":"World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases. https:\/\/www.who.int\/publications-detail\/laboratory-testing-for-2019-novel-coronavirus-insuspected-human-cases-20200117. [Accessed 25 March 2020]"},{"key":"84478_CR17","first-page":"171","volume":"11","author":"CF Aliferis","year":"2010","unstructured":"Aliferis, C. F., Statnikov, A., Tsamardinos, I., Mani, S. & Koutsoukos, X. D. Local causal and Markov blanket induction for causal discovery and feature selection for classification part I: algorithms and empirical evaluation. J. Mach. Learn. Res. 11, 171\u2013234 (2010).","journal-title":"J. Mach. Learn. Res."},{"key":"84478_CR18","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2019)."},{"key":"84478_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definition for sepsis and septic shock (sepsis-3). JAMA 315, 801\u2013810 (2016).","journal-title":"JAMA"},{"key":"84478_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/SHK.0000000000001023","volume":"50","author":"S Spoto","year":"2018","unstructured":"Spoto, S. et al. Procalcitonin and Mr-proadrenomedullin combination with sofa and qsofa scores for sepsis diagnosis and prognosis: a diagnostic algorithm. Shock 50, 44\u201352 (2018).","journal-title":"Shock"},{"key":"84478_CR21","doi-asserted-by":"publisher","first-page":"951532","DOI":"10.1155\/2015\/951532","volume":"2015","author":"S Angeletti","year":"2015","unstructured":"Angeletti, S. et al. Procalcitonin, MRProadrenomedullin, and cytokines measurement in sepsis diagnosis: advantages from test combination. Dis. Mark. 2015, 951532. https:\/\/doi.org\/10.1155\/2015\/951532 (2015).","journal-title":"Dis. Mark."},{"key":"84478_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.12.003","author":"E Bernal-Morell","year":"2017","unstructured":"Bernal-Morell, E. et al. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J. Infect. https:\/\/doi.org\/10.1016\/j.jinf.2017.12.003 (2017).","journal-title":"J. Infect."},{"key":"84478_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jama.1990.03450020096034","volume":"264","author":"MJ Tobin","year":"1990","unstructured":"Tobin, M. J. Respiratory monitoring. JAMA 264, 244\u2013251 (1990).","journal-title":"JAMA"},{"key":"84478_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13054-019-2613-4","volume":"23","author":"J Gonzalez Del Castillo","year":"2019","unstructured":"Gonzalez Del Castillo, J. et al. INFURG-SEMES investigators Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission. Crit. Care 23, 335. https:\/\/doi.org\/10.1186\/s13054-019-2613-4 (2019).","journal-title":"Crit. Care"},{"key":"84478_CR25","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","volume":"55","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 55, 102763 (2020).","journal-title":"EBioMedicine."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84478-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:42:45Z","timestamp":1670042565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84478-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84478"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84478-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CT has received funds for speaking at symposia organized on behalf of Pfizer, Novartis, Merck, Angelini, Thermofischer, Biomerieux, Basilea, Correvio, Zambon, Hikma and Astellas. All other authors: None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5121"}}